Irritable Bowel Syndrome. Irritable bowel syndrome with diarrhoea
Conditions
Interventions
Intervention 1: Receiving vitamin D from Zahrawi Company with 50,000 international units weekly in intervention group. Intervention 2: Filled with edible paraffin placebo produced by Zahrawi Co. was p
Treatment - Drugs
Placebo
Receiving vitamin D from Zahrawi Company with 50,000 international units weekly in intervention group
Filled with edible paraffin placebo produced by Zahrawi Co. was performed weekly in the control group
Sponsors
Vice Chancellor for Research,Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the study: aged between 18 and 65 years; suffering from irritable bowel syndrome ROME III criteria and completed the questionnaires; their disease severity score is between 175 and 300; BMI Between 18.5 to 34.9; a resident of Tehran; have diarrhea-predominant irritable bowel syndrome with form. Non-inclusion criteria: pregnant women or nursing mothers; a history of gastrointestinal diseases, including IBD, colorectal cancer and...; Gastrointestinal diseases such as celiac disease, is an infection of the gastrointestinal tract and ...; Abdominal surgery or radiation therapy, cholecystectomy, etc. The use of vitamin D supplements, six months before; Use of now any type of supplement or 3 months; probiotic supplement use; Antidepressants uses (Including serotonin receptor antagonists, tricyclic antidepressants, selective serotonin reuptake inhibitors, etc.); High-dose alcohol and caffeine 24 hours before the test; smoking 48 hours before the test; Exclusion criteria: Create any abnormal reactions to supplements; gastrointestinal bleeding; blood in the stool; rapid weight loss; the level of vitamin D normal (above 30 nmol / L); less than 80 percent of supplements; no intention to continue cooperation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical signs. Timepoint: Before and after 3 months of intervention. Method of measurement: ROME IV questionnaire and World Gastroenterology Organization questionnaire for the diagnosis of irritable bowel syndrome.;Severity of Clinical symptoms. Timepoint: Before and after 3 months of intervention. Method of measurement: IBS symptom severity questionnaire.;Quality of life. Timepoint: Before and after 3 months of intervention. Method of measurement: Irritable Bowel Syndrome Quality of Life Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety. Timepoint: Before and after 3 months of intervention. Method of measurement: Hospital Anxiety and Depression Scale(HADS).;Corticotropin Releasing Hormone. Timepoint: Before and after 3 months of intervention. Method of measurement: Elisea.;Interlukin-6. Timepoint: Before and after 3 months of intervention. Method of measurement: Elisea. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Khalighi Sikaroudi
Iran University Medical Sceinces
Outcome results
None listed